Compare Cassava Sciences Inc (FLNA) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Mondelez International (MDLZ) trades at $59.38, down 0.4% with a bearish technical signal despite beating earnings expectations for three consecutive quarters. The company maintains solid fundamentals with $38.54B revenue, 8.86% net margin, and strong analyst support (76% buy ratings). Recent developments include a dividend increase to $0.52 per share and new product launches like Toblerone Diamond Truffles.

MDLZ presents a compelling long-term opportunity with attractive valuation metrics (P/E 22.22) and 14% upside to consensus price target of $70.29. Key risks include cocoa cost pressures and competitive snack market dynamics, but the company's global brand strength and consistent execution support bullish outlook for patient investors.